Alterity Therapeutics Limited (NASDAQ: ATHE) was founded in 1997, formerly known as Prana Biotechnology Limited (formerly NASDAQ: PRAN), changed to its current name in April 2019, headquartered in Melbourne, Australia, with 14 full-time employees, and research and Develop therapeutic drugs for Alzheimer’s disease, Huntington’s disease, Parkinson’s disease and other neurological diseases.
Alterity Therapeutics Limited (ATHE):
Alterity Therapeutics Limited focuses on the research and development of drugs for Alzheimer’s disease, Huntington’s disease, and other age-related degenerative diseases. Prana Biotechnology is developing first-class treatments for orphan neurodegenerative diseases.
Alterity Therapeutics Limited’s main drug candidates include PBT434, the first of a new generation of small molecules designed to inhibit the aggregation of pathological proteins associated with neurodegeneration. PBT434 has been shown to reduce the abnormal accumulation of α-synuclein and tau in animal models of disease by restoring the normal iron balance in the brain. In this way, it has great potential to treat various forms of atypical Parkinson’s disease, such as multiple system atrophy (MSA) and progressive supranuclear palsy (PSP).
The drug PBT434 is undergoing phase I clinical trials for the treatment of Parkinson’s disease and other movement disorders; and PBT2, has completed four phase I studies and one phase IIa clinical trial for patients with Alzheimer’s disease.
Alterity Therapeutics Limited also completed the IMAGINE II biomarker imaging trial for Alzheimer’s disease; and the open-label IMAGINE Extension study for Huntington’s disease and the Reach2HD phase IIa trial.